SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

06 Nov 2024 Evaluate
The sales for the September 2024 quarter moved down to Rs. 3108.44 millions as compared to Rs. 4177.49 millions during the year-ago period.A big decline of -64.12% was reported for the quarter ended September 2024 to Rs. 319.59  millions from Rs. 890.65 millions of corresponding previous quarter.A decline of 656.75 millions was observed in the OP in the quarter ended September 2024 from 1403.46 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 3108.44 4177.49 -25.59 7504.46 7807.43 -3.88 15585.80 11911.98 30.84
Other Income 43.32 30.48 42.13 91.39 50.87 79.65 125.44 97.48 28.68
PBIDT 656.75 1403.46 -53.20 1943.08 2396.50 -18.92 4744.65 2810.56 68.82
Interest 10.63 44.33 -76.02 37.34 66.47 -43.82 139.97 130.67 7.12
PBDT 646.12 1359.13 -52.46 2112.00 2330.03 -9.36 4604.68 2679.89 71.82
Depreciation 160.73 145.08 10.79 323.52 280.94 15.16 596.99 527.76 13.12
PBT 485.39 1214.05 -60.02 1788.48 2049.09 -12.72 4007.69 2152.13 86.22
TAX 165.80 323.40 -48.73 485.50 536.20 -9.46 1011.73 520.94 94.21
Deferred Tax 43.68 9.03 383.72 57.57 12.36 365.78 15.87 17.04 -6.87
PAT 319.59 890.65 -64.12 1302.98 1512.89 -13.87 2995.96 1631.19 83.67
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.01 129.01 0.00
PBIDTM(%) 21.13 33.60 -37.11 25.89 30.70 -15.65 30.44 23.59 29.02

Neuland Laboratories Share Price

15100.00 168.55 (1.13%)
22-Apr-2026 14:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1667.70
Dr. Reddys Lab 1221.45
Cipla 1239.95
Zydus Lifesciences 932.80
Lupin 2310.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×